3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
45
Terminated
10
Unknown
7
Recruiting
6
Not yet recruiting
3
Withdrawn
1
No longer available
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Gynecologic
5
Genitourinary
4
Endocrine
4
NET
3
Tumor-Agnostic
2
Sarcoma
2
Other solid neoplasm
2
Other hematologic neoplasm
2
Head & Neck
2
Myeloid
1
Lymphoid
1
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Oxaliplatin
95
Fluorouracil
84
Capecitabine
75
Gemcitabine
72
Leucovorin
68
Nivolumab
67
Bevacizumab
63
pembrolizumab
60
Magnetic Resonance Spectroscopy
52
Specimen Handling
50
Irinotecan
50
durvalumab
46
Radiotherapy
42
atezolizumab
40
Cisplatin
39
Paclitaxel
37
Biopsy
37
130-nm albumin-bound paclitaxel
34
Cetuximab
30
Carboplatin
27
Albumin-Bound Paclitaxel
26
Taxes
24
Drug Therapy
20
dehydroftorafur
19
Radiation
19
Ipilimumab
19
tislelizumab
18
Surgical Procedures, Operative
17
Standard of Care
17
Docetaxel
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Everolimus
×
Gastrointestinal
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled